EA201591196A1 - Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств - Google Patents

Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств

Info

Publication number
EA201591196A1
EA201591196A1 EA201591196A EA201591196A EA201591196A1 EA 201591196 A1 EA201591196 A1 EA 201591196A1 EA 201591196 A EA201591196 A EA 201591196A EA 201591196 A EA201591196 A EA 201591196A EA 201591196 A1 EA201591196 A1 EA 201591196A1
Authority
EA
Eurasian Patent Office
Prior art keywords
transdermal delivery
methods
hormones
medicines
compositions
Prior art date
Application number
EA201591196A
Other languages
English (en)
Other versions
EA030797B1 (ru
Inventor
Эдвард Кайсак
Надир Буюктимкин
Сервет Буюктимкин
Джон Ньюсам
Цзюанье Вэнь
Дзутаро Судо
Амит Джаин
Original Assignee
ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. filed Critical ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК.
Publication of EA201591196A1 publication Critical patent/EA201591196A1/ru
Publication of EA030797B1 publication Critical patent/EA030797B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Изобретение относится к системам трансдермальной доставки, медицинским наборам и способам применения систем трансдермальной доставки и наборов в медицинских целях, таких как доставка контрацептивных средств для контроля репродуктивной функции.
EA201591196A 2012-12-21 2013-12-20 Система трансдермальной доставки гормонов (варианты) и способы ее применения EA030797B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740879P 2012-12-21 2012-12-21
PCT/US2013/076948 WO2014100599A1 (en) 2012-12-21 2013-12-20 Compositions and methods for transdermal delivery of hormones and other medicinal agents

Publications (2)

Publication Number Publication Date
EA201591196A1 true EA201591196A1 (ru) 2015-12-30
EA030797B1 EA030797B1 (ru) 2018-09-28

Family

ID=49943582

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591196A EA030797B1 (ru) 2012-12-21 2013-12-20 Система трансдермальной доставки гормонов (варианты) и способы ее применения

Country Status (11)

Country Link
US (2) US9144553B2 (ru)
EP (1) EP2934497B1 (ru)
JP (1) JP6336476B2 (ru)
CN (1) CN104936582B (ru)
AU (1) AU2013361106B2 (ru)
CA (1) CA2894696A1 (ru)
EA (1) EA030797B1 (ru)
ES (1) ES2613721T3 (ru)
MX (1) MX2015008021A (ru)
TW (1) TW201431572A (ru)
WO (1) WO2014100599A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015008021A (es) 2012-12-21 2016-03-04 Teikoku Pharma Usa Inc Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
US9314470B2 (en) 2012-12-28 2016-04-19 Noven Pharmaceuticals, Inc. Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol
US20160199317A1 (en) * 2013-08-30 2016-07-14 3M Innovative Properties Company Estradiol containing transdermal drug delivery systems and compositions
EP3226972A4 (en) 2014-12-01 2018-08-08 Achelios Therapeutics, Inc. Methods and compositions for treating migraine and conditions associated with pain
US9603967B2 (en) * 2015-05-08 2017-03-28 Vivex Biomedical, Inc. Placental tissue assembly
US20180125860A1 (en) * 2015-05-18 2018-05-10 Agile Therapeutics, Inc. Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects
US20170000745A1 (en) * 2015-07-02 2017-01-05 Noven Pharmaceuticals, Inc. Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol
US20180369174A1 (en) * 2015-12-16 2018-12-27 Achelios Therapeutics, Inc. Methods and compositions for treating peripheral neuropathy
WO2017172603A1 (en) * 2016-03-28 2017-10-05 Tioga Research, Inc. Topical formulation
US20190160020A1 (en) * 2016-07-06 2019-05-30 Agile Therapeutics, Inc. Transdermal Packaging Membranes
CA3061323C (en) 2017-04-30 2023-09-26 Versi Group, Llc An opioid for use to reduce and/or treat drug addiction

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296230A (en) 1985-02-25 1994-03-22 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US5560922A (en) 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4863738A (en) * 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5788983A (en) 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6024974A (en) 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
US7384650B2 (en) 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
IL149655A0 (en) * 1999-11-24 2002-11-10 Agile Therapeutics Inc Improved transdermal contraceptive delivery system and process
CA2483834A1 (en) 2002-05-30 2003-12-11 Angela Anigbogu Norethindrone sustained release formulations and methods associated therewith
US8778382B2 (en) 2003-04-30 2014-07-15 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
ITRM20030596A1 (it) 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
US7468470B2 (en) 2004-03-26 2008-12-23 Schering Ag Medicinal patch that leaves less adhesive residue when removed
WO2006036899A2 (en) 2004-09-27 2006-04-06 Corium International, Inc. Transdermal systems for the delivery of estrogens and progestins
US7795309B2 (en) 2006-03-06 2010-09-14 Fqubed Inc. Topical formulation including diclofenac, or a pharmaceutically acceptable salt thereof
BRPI0717769A2 (pt) 2006-10-17 2013-11-05 Nuvo Res Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
NZ582565A (en) 2007-07-10 2012-07-27 Agile Therapeutics Inc Dermal delivery device with in situ seal
AR068408A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Pulverizacion de hormonas transdermicas
US20090098191A1 (en) 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
AU2008327436B2 (en) * 2007-11-22 2013-09-05 Medrx Co., Ltd. External preparation composition comprising fatty acid-based ionic liquid as active ingredient
US20090297590A1 (en) * 2008-05-30 2009-12-03 Masahiro Yamaji Ketotifen transdermal drug delivery systems and methods for treating ophthalmic disease
US9192614B2 (en) 2008-10-08 2015-11-24 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
ES2795455T3 (es) 2008-10-08 2020-11-23 Agile Therapeutics Inc Suministro transdérmico
EP2349337A1 (en) 2008-11-06 2011-08-03 Nuvo Research Inc. Formulations for the treatment of acute herpes zoster pain
WO2011014850A2 (en) 2009-07-31 2011-02-03 Nuvo Research Inc. Topical eutectic-based formulations
EP2470172A1 (en) 2009-08-26 2012-07-04 Nuvo Research Inc. Pharmaceutical formulations and methods of use
WO2011041609A2 (en) 2009-09-30 2011-04-07 Nuvo Research Inc. Topical formulations
WO2011044540A1 (en) 2009-10-09 2011-04-14 Nuvo Research Inc. Topical formulation comprising etoricoxib and a zwitterionic surfactant
WO2011060195A2 (en) 2009-11-11 2011-05-19 Nuvo Research Inc. Topical eutectic formulation
WO2011063531A1 (en) 2009-11-27 2011-06-03 Nuvo Research Inc. Topical ibuprofen formulations
EP2544659A2 (en) 2009-12-23 2013-01-16 Nuvo Research Inc. Highly permeating terbinafine formulation for treating onychomycosis
WO2011088072A2 (en) 2010-01-14 2011-07-21 Agile Therapeutics, Inc. Dermal delivery device
CA2828086C (en) 2010-03-10 2018-07-31 Nuvo Research Inc. Foamable formulation
KR20120137373A (ko) 2010-04-30 2012-12-20 테이코쿠 팔마 유에스에이, 인코포레이티드 프로필아미노인단 경피 조성물
EP2575813A1 (en) 2010-05-28 2013-04-10 Nuvo Research Inc. Topical etoricoxib formulation
DK2640389T3 (en) 2010-11-17 2015-03-09 Hexal Ag Transdermal therapeutic system comprising buprenorphine
MX2015008021A (es) 2012-12-21 2016-03-04 Teikoku Pharma Usa Inc Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.

Also Published As

Publication number Publication date
CN104936582B (zh) 2018-12-21
ES2613721T3 (es) 2017-05-25
EP2934497B1 (en) 2016-11-23
JP2016503802A (ja) 2016-02-08
US20140178459A1 (en) 2014-06-26
EP2934497A1 (en) 2015-10-28
AU2013361106B2 (en) 2017-06-01
WO2014100599A1 (en) 2014-06-26
MX2015008021A (es) 2016-03-04
TW201431572A (zh) 2014-08-16
US20160051487A1 (en) 2016-02-25
AU2013361106A1 (en) 2015-07-02
US9579296B2 (en) 2017-02-28
CA2894696A1 (en) 2014-06-26
EA030797B1 (ru) 2018-09-28
US9144553B2 (en) 2015-09-29
CN104936582A (zh) 2015-09-23
JP6336476B2 (ja) 2018-06-06

Similar Documents

Publication Publication Date Title
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
CY1121843T1 (el) Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
UY35661A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que lo s contienen
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
BR112015029462A8 (pt) Inibidores de quinase
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
BR112016001876A2 (pt) composto de benzoxaborol tricíclico, método de preparação e uso do mesmo
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU